Donna Peehl, PhD
Professor
Adjunct Professor
Biography
Donna Peehl, PhD, is Professor in the Body Imaging Research Group in the Department of Radiology and Biomedical Imaging at the University of California, San Francisco. She received her undergraduate degree in biology at Stanford University in California and completed her PhD in Molecular, Cellular and Developmental Biology at the University of Colorado in Boulder. During postdoctoral fellowship research at the University of California in Irvine and San Francisco, she investigated tumor suppressor genes and oncogenes in cancer. Prior to joining UCSF, Dr. Peehl became Professor Emerita at Stanford University, California, after 35 years as a basic scientist in the Department of Urology. She is widely recognized for her work in developing realistic and representative preclinical cell and tissue models of prostate and kidney cancer.
Dr. Peehl’s current studies focus on developing novel therapeutics for prostate and kidney cancer. In collaboration with investigators at UCSF and Stanford, she is testing novel inhibitors of the tyrosine kinase AXL and of the scaffold protein, IQGAP, for their anti-cancer activity in her patient-derived models of kidney cancer. Another project uses tissue slice cultures to investigate cancer-associated glycosylation as a novel immunotherapy target. Under the auspices of a new NIH U01 grant, Dr. Peehl is collaborating with Dr. John Kurhanewicz and others at UCSF to compare metabolism of four types of kidney cancer preclinical models by hyperpolarized molecular imaging.
Dr. Peehl has been the recipient of numerous grants from the NIH and Department of Defense (DoD) Prostate Cancer Research Program, and has received awards from the Prostate Cancer Foundation (formerly CaP CURE) to support her research. She has served as chair or scientist reviewer for many NIH and grant review panels and has reviewed or served on the editorial board for a large number of scientific journals. Her peer-reviews include over 200 articles and publications.
Expertise:
Urology
Specialty:
Prostate cancer, kidney cancer, molecular and cellular biology
Professional Interests:
Patient-derived xenografts, tissue slice cultures, primary cultures, spheroid cultures, preclinical drug testing, biomarkers, metabolism, cancer biology, translational science
Education
Undergraduate, - Biology, Stanford University, California
Postdoctoral Fellow, - Tumor Suppressors, University of California, Irvine
Postdoctoral Fellow, - Oncogenes, University of California, San Francisco
Doctor of Philosophy, - Molecular, Cellular and Developmental Biology, University of Colorado, Boulder
Honors and Awards
Award for Excellence in Urologic Research, SWIU/SBUR, 2016
Publications
Habowski AN, Budagavi DP, Scherer SD, Aurora AB, Caligiuri G, Flynn WF, Langer EM, Brody JR, Sears RC, Foggetti G, Arnal Estape A, Nguyen DX, Politi KA, Shen X, Hsu DS, Peehl DM, Kurhanewicz J, Sriram R, Suarez M, Xiao S, Du Y, Li XN, Navone NM, Labanca E, Willey CD. Patient-Derived Models of Cancer in the NCI PDMC Consortium: Selection, Pitfalls, and Practical Recommendations. Cancers (Basel). 2024 Jan 29; 16(3).
Peehl DM, Badea CT, Chenevert TL, Daldrup-Link HE, Ding L, Dobrolecki LE, Houghton AM, Kinahan PE, Kurhanewicz J, Lewis MT, Li S, Luker GD, Ma CX, Manning HC, Mowery YM, O'Dwyer PJ, Pautler RG, Rosen MA, Roudi R, Ross BD, Shoghi KI, Sriram R, Talpaz M, Wahl RL, Zhou R. Animal Models and Their Role in Imaging-Assisted Co-Clinical Trials. Tomography. 2023 03 16; 9(2):657-680.
Agudelo JP, Upadhyay D, Zhang D, Zhao H, Nolley R, Sun J, Agarwal S, Bok RA, Vigneron DB, Brooks JD, Kurhanewicz J, Peehl DM, Sriram R. Multiparametric Magnetic Resonance Imaging and Metabolic Characterization of Patient-Derived Xenograft Models of Clear Cell Renal Cell Carcinoma. Metabolites. 2022 Nov 15; 12(11).
Zhang D, Wornow S, Peehl DM, Rankin EB, Brooks JD. The controversial role and therapeutic development of the m6A demethylase FTO in renal cell carcinoma. Transl Oncol. 2022 Nov; 25:101518.
Rice MA, Kumar V, Tailor D, Garcia-Marques FJ, Hsu EC, Liu S, Bermudez A, Kanchustambham V, Shankar V, Inde Z, Alabi BR, Muruganantham A, Shen M, Pandrala M, Nolley R, Aslan M, Ghoochani A, Agarwal A, Buckup M, Kumar M, Going CC, Peehl DM, Dixon SJ, Zare RN, Brooks JD, Pitteri SJ, Malhotra SV, Stoyanova T. SU086, an inhibitor of HSP90, impairs glycolysis and represents a treatment strategy for advanced prostate cancer. Cell Rep Med. 2022 02 15; 3(2):100502.
Jillson LK, Rider LC, Rodrigues LU, Romero L, Karimpour-Fard A, Nieto C, Gillette C, Torkko K, Danis E, Smith EE, Nolley R, Peehl DM, Lucia MS, Costello JC, Cramer SD. MAP3K7 Loss Drives Enhanced Androgen Signaling and Independently Confers Risk of Recurrence in Prostate Cancer with Joint Loss of CHD1. Mol Cancer Res. 2021 07; 19(7):1123-1136.
Sun J, Bok RA, DeLos Santos J, Upadhyay D, DeLos Santos R, Agarwal S, Van Criekinge M, Vigneron DB, Aggarwal R, Peehl DM, Kurhanewicz J, Sriram R. Resistance to Androgen Deprivation Leads to Altered Metabolism in Human and Murine Prostate Cancer Cell and Tumor Models. Metabolites. 2021 Feb 26; 11(3).
Xiao Y, Thakkar KN, Zhao H, Broughton J, Li Y, Seoane JA, Diep AN, Metzner TJ, von Eyben R, Dill DL, Brooks JD, Curtis C, Leppert JT, Ye J, Peehl DM, Giaccia AJ, Sinha S, Rankin EB. The m6A RNA demethylase FTO is a HIF-independent synthetic lethal partner with the VHL tumor suppressor. Proc Natl Acad Sci U S A. 2020 09 01; 117(35):21441-21449.
Sriram R, Van Criekinge M, DeLos Santos J, Ahamed F, Qin H, Nolley R, Santos RD, Tabatabai ZL, Bok RA, Keshari KR, Vigneron DB, Peehl DM, Kurhanewicz J. Elevated Tumor Lactate and Efflux in High-grade Prostate Cancer demonstrated by Hyperpolarized 13C Magnetic Resonance Spectroscopy of Prostate Tissue Slice Cultures. Cancers (Basel). 2020 Feb 26; 12(3).
Hsu EC, Rice MA, Bermudez A, Marques FJG, Aslan M, Liu S, Ghoochani A, Zhang CA, Chen YS, Zlitni A, Kumar S, Nolley R, Habte F, Shen M, Koul K, Peehl DM, Zoubeidi A, Gambhir SS, Kunder CA, Pitteri SJ, Brooks JD, Stoyanova T. Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1. Proc Natl Acad Sci U S A. 2020 01 28; 117(4):2032-2042.
Xiao Y, Zhao H, Tian L, Nolley R, Diep AN, Ernst A, Fuh KC, Miao YR, von Eyben R, Leppert JT, Brooks JD, Peehl DM, Giaccia AJ, Rankin EB. S100A10 Is a Critical Mediator of GAS6/AXL-Induced Angiogenesis in Renal Cell Carcinoma. Cancer Res. 2019 11 15; 79(22):5758-5768.
Gong X, Zhao H, Saar M, Peehl DM, Brooks JD. miR-22 Regulates Invasion, Gene Expression and Predicts Overall Survival in Patients with Clear Cell Renal Cell Carcinoma. Kidney Cancer. 2019 Aug 07; 3(2):119-132.
Bancroft Brown J, Sriram R, VanCriekinge M, Delos Santos R, Sun J, Delos Santos J, Tabatabai ZL, Shinohara K, Nguyen H, Peehl DM, Kurhanewicz J. NMR quantification of lactate production and efflux and glutamate fractional enrichment in living human prostate biopsies cultured with [1,6-13 C2 ]glucose. Magn Reson Med. 2019 08; 82(2):566-576.
Spiciarich DR, Nolley R, Maund SL, Purcell SC, Herschel J, Iavarone AT, Peehl DM, Bertozzi CR. Bioorthogonal Labeling of Human Prostate Cancer Tissue Slice Cultures for Glycoproteomics. Angew Chem Int Ed Engl. 2017 07 24; 56(31):8992-8997.
Zhao H, Ning S, Nolley R, Scicinski J, Oronsky B, Knox SJ, Peehl DM. The immunomodulatory anticancer agent, RRx-001, induces an interferon response through epigenetic induction of viral mimicry. Clin Epigenetics. 2017; 9:4.
Oronsky B, Paulmurugan R, Foygel K, Scicinski J, Knox SJ, Peehl D, Zhao H, Ning S, Cabrales P, Summers TA, Reid TR, Fitch WL, Kim MM, Trepel JB, Lee MJ, Kesari S, Abrouk ND, Day RM, Oronsky A, Ray CM, Carter CA. RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials. Expert Opin Investig Drugs. 2017 01; 26(1):109-119.
Zhao H, Nolley R, Chan AMW, Rankin EB, Peehl DM. Cabozantinib inhibits tumor growth and metastasis of a patient-derived xenograft model of papillary renal cell carcinoma with MET mutation. Cancer Biol Ther. 2017 Nov 02; 18(11):863-871.
Türkcan S, Naczynski DJ, Nolley R, Sasportas LS, Peehl DM, Pratx G. Endoscopic detection of cancer with lensless radioluminescence imaging and machine vision. Sci Rep. 2016 08 01; 6:30737.
Sriram R, Van Criekinge M, DeLos Santos J, Keshari KR, Wilson DM, Peehl D, Kurhanewicz J, Wang ZJ. Non-invasive differentiation of benign renal tumors from clear cell renal cell carcinomas using clinically translatable hyperpolarized 13C pyruvate magnetic resonance. Tomography. 2016 Mar; 2(1):35-42.
Valta MP, Zhao H, Saar M, Tuomela J, Nolley R, Linxweiler J, Sandholm J, Lehtimäki J, Härkönen P, Coleman I, Nelson PS, Corey E, Peehl DM. Spheroid culture of LuCaP 136 patient-derived xenograft enables versatile preclinical models of prostate cancer. Clin Exp Metastasis. 2016 Apr; 33(4):325-37.
Zhao H, Leppert JT, Peehl DM. A Protective Role for Androgen Receptor in Clear Cell Renal Cell Carcinoma Based on Mining TCGA Data. PLoS One. 2016; 11(1):e0146505.
Zhao H, Ning S, Scicinski J, Oronsky B, Knox SJ, Peehl DM. Epigenetic effects of RRx-001: a possible unifying mechanism of anticancer activity. Oncotarget. 2015 Dec 22; 6(41):43172-81.
Keshari KR, Wilson DM, Van Criekinge M, Sriram R, Koelsch BL, Wang ZJ, VanBrocklin HF, Peehl DM, O'Brien T, Sampath D, Carano RA, Kurhanewicz J. Metabolic response of prostate cancer to nicotinamide phophoribosyltransferase inhibition in a hyperpolarized MR/PET compatible bioreactor. Prostate. 2015 Oct; 75(14):1601-9.
Mihelich BL, Maranville JC, Nolley R, Peehl DM, Nonn L. Elevated serum microRNA levels associate with absence of high-grade prostate cancer in a retrospective cohort. PLoS One. 2015; 10(4):e0124245.
Tesfay L, Clausen KA, Kim JW, Hegde P, Wang X, Miller LD, Deng Z, Blanchette N, Arvedson T, Miranti CK, Babitt JL, Lin HY, Peehl DM, Torti FM, Torti SV. Hepcidin regulation in prostate and its disruption in prostate cancer. Cancer Res. 2015 Jun 01; 75(11):2254-63.
Rodrigues LU, Rider L, Nieto C, Romero L, Karimpour-Fard A, Loda M, Lucia MS, Wu M, Shi L, Cimic A, Sirintrapun SJ, Nolley R, Pac C, Chen H, Peehl DM, Xu J, Liu W, Costello JC, Cramer SD. Coordinate loss of MAP3K7 and CHD1 promotes aggressive prostate cancer. Cancer Res. 2015 Mar 15; 75(6):1021-34.
Cerchiari AE, Garbe JC, Jee NY, Todhunter ME, Broaders KE, Peehl DM, Desai TA, LaBarge MA, Thomson M, Gartner ZJ. A strategy for tissue self-organization that is robust to cellular heterogeneity and plasticity. Proc Natl Acad Sci U S A. 2015 Feb 17; 112(7):2287-92.
Wang Y, Roma A, Nolley R, Abdul-Karim F, Peehl DM, Eng C. Nuclear KLLN expression associates with improved relapse-free survival for prostate carcinoma. Endocr Relat Cancer. 2014 Aug; 21(4):579-86.
Saar M, Zhao H, Nolley R, Young SR, Coleman I, Nelson PS, Vessella RL, Peehl DM. Spheroid culture of LuCaP 147 as an authentic preclinical model of prostate cancer subtype with SPOP mutation and hypermutator phenotype. Cancer Lett. 2014 Sep 01; 351(2):272-80.
Valta MP, Zhao H, Ingels A, Thong AE, Nolley R, Saar M, Peehl DM. Development of a realistic in vivo bone metastasis model of human renal cell carcinoma. Clin Exp Metastasis. 2014 Jun; 31(5):573-84.
Pu K, Shuhendler AJ, Valta MP, Cui L, Saar M, Peehl DM, Rao J. Phosphorylcholine-coated semiconducting polymer nanoparticles as rapid and efficient labeling agents for in vivo cell tracking. Adv Healthc Mater. 2014 Aug; 3(8):1292-8.
Maund SL, Nolley R, Peehl DM. Optimization and comprehensive characterization of a faithful tissue culture model of the benign and malignant human prostate. Lab Invest. 2014 Feb; 94(2):208-21.
Belardi B, de la Zerda A, Spiciarich DR, Maund SL, Peehl DM, Bertozzi CR. Imaging the glycosylation state of cell surface glycoproteins by two-photon fluorescence lifetime imaging microscopy. Angew Chem Int Ed Engl. 2013 Dec 23; 52(52):14045-9.
Ingels A, Zhao H, Thong AE, Saar M, Valta MP, Nolley R, Santos J, Peehl DM. Preclinical trial of a new dual mTOR inhibitor, MLN0128, using renal cell carcinoma tumorgrafts. Int J Cancer. 2014 May 15; 134(10):2322-9.
Af Hällström TM, Zhao H, Tian J, Rantanen V, Reese SW, Nolley R, Laiho M, Peehl DM. A tissue graft model of DNA damage response in the normal and malignant human prostate. J Urol. 2014 Mar; 191(3):842-9.
Zhao H, Thong A, Nolley R, Reese SW, Santos J, Ingels A, Peehl DM. Patient-derived tissue slice grafts accurately depict response of high-risk primary prostate cancer to androgen deprivation therapy. J Transl Med. 2013 Aug 28; 11:199.
Thong AE, Zhao H, Ingels A, Valta MP, Nolley R, Santos J, Young SR, Peehl DM. Tissue slice grafts of human renal cell carcinoma: an authentic preclinical model with high engraftment rate and metastatic potential. Urol Oncol. 2014 Jan; 32(1):43.e23-30.
Young SR, Saar M, Santos J, Nguyen HM, Vessella RL, Peehl DM. Establishment and serial passage of cell cultures derived from LuCaP xenografts. Prostate. 2013 Sep; 73(12):1251-62.
Zhao H, Sun N, Young SR, Nolley R, Santos J, Wu JC, Peehl DM. Induced pluripotency of human prostatic epithelial cells. PLoS One. 2013; 8(5):e64503.
Keshari KR, Sriram R, Van Criekinge M, Wilson DM, Wang ZJ, Vigneron DB, Peehl DM, Kurhanewicz J. Metabolic reprogramming and validation of hyperpolarized 13C lactate as a prostate cancer biomarker using a human prostate tissue slice culture bioreactor. Prostate. 2013 Aug; 73(11):1171-81.
Wang D, Dafik L, Nolley R, Huang W, Wolfinger RD, Wang LX, Peehl DM. Anti-Oligomannose Antibodies as Potential Serum Biomarkers of Aggressive Prostate Cancer. Drug Dev Res. 2013 Mar; 74(2):65-80.
Zhao H, Coram MA, Nolley R, Reese SW, Young SR, Peehl DM. Transcript levels of androgen receptor variant AR-V1 or AR-V7 do not predict recurrence in patients with prostate cancer at indeterminate risk for progression. J Urol. 2012 Dec; 188(6):2158-64.
Tian J, Zhao H, Nolley R, Reese SW, Young SR, Li X, Peehl DM, Knox SJ. Darinaparsin: solid tumor hypoxic cytotoxin and radiosensitizer. Clin Cancer Res. 2012 Jun 15; 18(12):3366-76.
Hughes AJ, Lin RK, Peehl DM, Herr AE. Microfluidic integration for automated targeted proteomic assays. Proc Natl Acad Sci U S A. 2012 Apr 17; 109(16):5972-7.
Hubbard SC, Boyce M, McVaugh CT, Peehl DM, Bertozzi CR. Cell surface glycoproteomic analysis of prostate cancer-derived PC-3 cells. Bioorg Med Chem Lett. 2011 Sep 01; 21(17):4945-50.
Kobayashi Y, Absher DM, Gulzar ZG, Young SR, McKenney JK, Peehl DM, Brooks JD, Myers RM, Sherlock G. DNA methylation profiling reveals novel biomarkers and important roles for DNA methyltransferases in prostate cancer. Genome Res. 2011 Jul; 21(7):1017-27.
Peehl DM, Chen Z, Nolley R. Serum Mac-2BP does not distinguish men with high grade, large volume prostate cancer from men with benign prostatic hyperplasia. Prostate. 2011 Jan 01; 71(1):26-31.
Peng Q, Omata S, Peehl DM, Constantinou CE. Stiffness mapping prostate biopsy samples using a tactile sensor. Annu Int Conf IEEE Eng Med Biol Soc. 2011; 2011:8515-8.
Tian J, Peehl DM, Zheng W, Knox SJ. Anti-tumor and radiosensitization activities of the iron chelator HDp44mT are mediated by effects on intracellular redox status. Cancer Lett. 2010 Dec 08; 298(2):231-7.
Zhao H, Nolley R, Chen Z, Peehl DM. Tissue slice grafts: an in vivo model of human prostate androgen signaling. Am J Pathol. 2010 Jul; 177(1):229-39.
Flamand V, Zhao H, Peehl DM. Targeting monoamine oxidase A in advanced prostate cancer. J Cancer Res Clin Oncol. 2010 Nov; 136(11):1761-71.
Levin YS, Albers MJ, Butler TN, Spielman D, Peehl DM, Kurhanewicz J. Methods for metabolic evaluation of prostate cancer cells using proton and (13)C HR-MAS spectroscopy and [3-(13)C] pyruvate as a metabolic substrate. Magn Reson Med. 2009 Nov; 62(5):1091-8.
Zhao H, Flamand V, Peehl DM. Anti-oncogenic and pro-differentiation effects of clorgyline, a monoamine oxidase A inhibitor, on high grade prostate cancer cells. BMC Med Genomics. 2009 Aug 20; 2:55.
Zhao H, Peehl DM. Tumor-promoting phenotype of CD90hi prostate cancer-associated fibroblasts. Prostate. 2009 Jun 15; 69(9):991-1000.
Swami S, Krishnan AV, Moreno J, Bhattacharyya RS, Gardner C, Brooks JD, Peehl DM, Feldman D. Inhibition of prostaglandin synthesis and actions by genistein in human prostate cancer cells and by soy isoflavones in prostate cancer patients. Int J Cancer. 2009 May 01; 124(9):2050-9.
Peehl DM, Coram M, Khine H, Reese S, Nolley R, Zhao H. The significance of monoamine oxidase-A expression in high grade prostate cancer. J Urol. 2008 Nov; 180(5):2206-11.
Cramer SD, Sun J, Zheng SL, Xu J, Peehl DM. Association of prostate-specific antigen promoter genotype with clinical and histopathologic features of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2008 Sep; 17(9):2451-7.
Kim J, Choi YL, Vallentin A, Hunrichs BS, Hellerstein MK, Peehl DM, Mochly-Rosen D. Centrosomal PKCbetaII and pericentrin are critical for human prostate cancer growth and angiogenesis. Cancer Res. 2008 Aug 15; 68(16):6831-9.
Das S, Hahn Y, Walker DA, Nagata S, Willingham MC, Peehl DM, Bera TK, Lee B, Pastan I. Topology of NGEP, a prostate-specific cell:cell junction protein widely expressed in many cancers of different grade level. Cancer Res. 2008 Aug 01; 68(15):6306-12.
Pienta KJ, Abate-Shen C, Agus DB, Attar RM, Chung LW, Greenberg NM, Hahn WC, Isaacs JT, Navone NM, Peehl DM, Simons JW, Solit DB, Soule HR, VanDyke TA, Weber MJ, Wu L, Vessella RL. The current state of preclinical prostate cancer animal models. Prostate. 2008 May 01; 68(6):629-39.
Zhao H, Nolley R, Chen Z, Reese SW, Peehl DM. Inhibition of monoamine oxidase A promotes secretory differentiation in basal prostatic epithelial cells. Differentiation. 2008 Sep; 76(7):820-30.
Krishnan AV, Swami S, Moreno J, Bhattacharyya RB, Peehl DM, Feldman D. Potentiation of the growth-inhibitory effects of vitamin D in prostate cancer by genistein. Nutr Rev. 2007 Aug; 65(8 Pt 2):S121-3.
Feldman D, Krishnan A, Moreno J, Swami S, Peehl DM, Srinivas S. Vitamin D inhibition of the prostaglandin pathway as therapy for prostate cancer. Nutr Rev. 2007 Aug; 65(8 Pt 2):S113-5.
Krishnan AV, Moreno J, Nonn L, Malloy P, Swami S, Peng L, Peehl DM, Feldman D. Novel pathways that contribute to the anti-proliferative and chemopreventive activities of calcitriol in prostate cancer. J Steroid Biochem Mol Biol. 2007 Mar; 103(3-5):694-702.
Swami S, Krishnan AV, Moreno J, Bhattacharyya RB, Peehl DM, Feldman D. Calcitriol and genistein actions to inhibit the prostaglandin pathway: potential combination therapy to treat prostate cancer. J Nutr. 2007 01; 137(1 Suppl):205S-210S.
Zhao H, Ramos CF, Brooks JD, Peehl DM. Distinctive gene expression of prostatic stromal cells cultured from diseased versus normal tissues. J Cell Physiol. 2007 Jan; 210(1):111-21.
Murayama Y, Omata S, Yajima T, Peng Q, Shishido K, Peehl DM, Constantinou CE. High resolution regional elasticity mapping of the human prostate. Annu Int Conf IEEE Eng Med Biol Soc. 2007; 2007:5803-6.
Nonn L, Duong D, Peehl DM. Chemopreventive anti-inflammatory activities of curcumin and other phytochemicals mediated by MAP kinase phosphatase-5 in prostate cells. Carcinogenesis. 2007 Jun; 28(6):1188-96.
Bauman DR, Steckelbroeck S, Peehl DM, Penning TM. Transcript profiling of the androgen signal in normal prostate, benign prostatic hyperplasia, and prostate cancer. Endocrinology. 2006 Dec; 147(12):5806-16.
Nonn L, Peng L, Feldman D, Peehl DM. Inhibition of p38 by vitamin D reduces interleukin-6 production in normal prostate cells via mitogen-activated protein kinase phosphatase 5: implications for prostate cancer prevention by vitamin D. Cancer Res. 2006 Apr 15; 66(8):4516-24.
Vaday GG, Peehl DM, Kadam PA, Lawrence DM. Expression of CCL5 (RANTES) and CCR5 in prostate cancer. Prostate. 2006 Feb 01; 66(2):124-34.
Husbeck B, Nonn L, Peehl DM, Knox SJ. Tumor-selective killing by selenite in patient-matched pairs of normal and malignant prostate cells. Prostate. 2006 Feb 01; 66(2):218-25.
Chen N, Szentirmay MN, Pawar SA, Sirito M, Wang J, Wang Z, Zhai Q, Yang HX, Peehl DM, Ware JL, Sawadogo M. Tumor-suppression function of transcription factor USF2 in prostate carcinogenesis. Oncogene. 2006 Jan 26; 25(4):579-87.
Rose A, Xu Y, Chen Z, Fan Z, Stamey TA, McNeal JE, Caldwell M, Peehl DM. Comparative gene and protein expression in primary cultures of epithelial cells from benign prostatic hyperplasia and prostate cancer. Cancer Lett. 2005 Sep 28; 227(2):213-22.
Swami S, Krishnan AV, Peehl DM, Feldman D. Genistein potentiates the growth inhibitory effects of 1,25-dihydroxyvitamin D3 in DU145 human prostate cancer cells: role of the direct inhibition of CYP24 enzyme activity. Mol Cell Endocrinol. 2005 Sep 28; 241(1-2):49-61.
Bauman DR, Steckelbroeck S, Williams MV, Peehl DM, Penning TM. Identification of the major oxidative 3alpha-hydroxysteroid dehydrogenase in human prostate that converts 5alpha-androstane-3alpha,17beta-diol to 5alpha-dihydrotestosterone: a potential therapeutic target for androgen-dependent disease. Mol Endocrinol. 2006 Feb; 20(2):444-58.
Zhao H, Lai F, Nonn L, Brooks JD, Peehl DM. Molecular targets of doxazosin in human prostatic stromal cells. Prostate. 2005 Mar 01; 62(4):400-10.
Peehl DM. Primary cell cultures as models of prostate cancer development. Endocr Relat Cancer. 2005 Mar; 12(1):19-47.
Dallas SL, Zhao S, Cramer SD, Chen Z, Peehl DM, Bonewald LF. Preferential production of latent transforming growth factor beta-2 by primary prostatic epithelial cells and its activation by prostate-specific antigen. J Cell Physiol. 2005 Feb; 202(2):361-70.
Husbeck B, Peehl DM, Knox SJ. Redox modulation of human prostate carcinoma cells by selenite increases radiation-induced cell killing. Free Radic Biol Med. 2005 Jan 01; 38(1):50-7.
Peehl DM, Feldman D. Interaction of nuclear receptor ligands with the Vitamin D signaling pathway in prostate cancer. J Steroid Biochem Mol Biol. 2004 Nov; 92(4):307-15.
San Francisco IF, DeWolf WC, Peehl DM, Olumi AF. Expression of transforming growth factor-beta 1 and growth in soft agar differentiate prostate carcinoma-associated fibroblasts from normal prostate fibroblasts. Int J Cancer. 2004 Nov 01; 112(2):213-8.
Lee KL, Peehl DM. Molecular and cellular pathogenesis of benign prostatic hyperplasia. J Urol. 2004 Nov; 172(5 Pt 1):1784-91.
Peehl DM, Shinghal R, Nonn L, Seto E, Krishnan AV, Brooks JD, Feldman D. Molecular activity of 1,25-dihydroxyvitamin D3 in primary cultures of human prostatic epithelial cells revealed by cDNA microarray analysis. J Steroid Biochem Mol Biol. 2004 Oct; 92(3):131-41.
Khanim FL, Gommersall LM, Wood VH, Smith KL, Montalvo L, O'Neill LP, Xu Y, Peehl DM, Stewart PM, Turner BM, Campbell MJ. Altered SMRT levels disrupt vitamin D3 receptor signalling in prostate cancer cells. Oncogene. 2004 Sep 02; 23(40):6712-25.
Ma JF, Nonn L, Campbell MJ, Hewison M, Feldman D, Peehl DM. Mechanisms of decreased Vitamin D 1alpha-hydroxylase activity in prostate cancer cells. Mol Cell Endocrinol. 2004 Jun 30; 221(1-2):67-74.
Krishnan AV, Shinghal R, Raghavachari N, Brooks JD, Peehl DM, Feldman D. Analysis of vitamin D-regulated gene expression in LNCaP human prostate cancer cells using cDNA microarrays. Prostate. 2004 May 15; 59(3):243-51.
Peehl DM. Are primary cultures realistic models of prostate cancer? J Cell Biochem. 2004 Jan 01; 91(1):185-95.
He XY, Yang YZ, Peehl DM, Lauderdale A, Schulz H, Yang SY. Oxidative 3alpha-hydroxysteroid dehydrogenase activity of human type 10 17beta-hydroxysteroid dehydrogenase. J Steroid Biochem Mol Biol. 2003 Nov; 87(2-3):191-8.
Krajewska M, Krajewski S, Banares S, Huang X, Turner B, Bubendorf L, Kallioniemi OP, Shabaik A, Vitiello A, Peehl D, Gao GJ, Reed JC. Elevated expression of inhibitor of apoptosis proteins in prostate cancer. Clin Cancer Res. 2003 Oct 15; 9(13):4914-25.
Rizner TL, Lin HK, Peehl DM, Steckelbroeck S, Bauman DR, Penning TM. Human type 3 3alpha-hydroxysteroid dehydrogenase (aldo-keto reductase 1C2) and androgen metabolism in prostate cells. Endocrinology. 2003 Jul; 144(7):2922-32.
Peehl DM, Krishnan AV, Feldman D. Pathways mediating the growth-inhibitory actions of vitamin D in prostate cancer. J Nutr. 2003 07; 133(7 Suppl):2461S-2469S.
Xu Y, Iyengar S, Roberts RL, Shappell SB, Peehl DM. Primary culture model of peroxisome proliferator-activated receptor gamma activity in prostate cancer cells. J Cell Physiol. 2003 Jul; 196(1):131-43.
Peehl DM, Feldman D. The role of vitamin D and retinoids in controlling prostate cancer progression. Endocr Relat Cancer. 2003 Jun; 10(2):131-40.
Moore MG, Wetterau LA, Francis MJ, Peehl DM, Cohen P. Novel stimulatory role for insulin-like growth factor binding protein-2 in prostate cancer cells. Int J Cancer. 2003 May 20; 105(1):14-9.
Lecane PS, Kiviharju TM, Sellers RG, Peehl DM. Leptomycin B stabilizes and activates p53 in primary prostatic epithelial cells and induces apoptosis in the LNCaP cell line. Prostate. 2003 Mar 01; 54(4):258-67.
Peehl DM. Growth of prostatic epithelial and stromal cells in vitro. Methods Mol Med. 2003; 81:41-57.
Krishnan AV, Peehl DM, Feldman D. The role of vitamin D in prostate cancer. Recent Results Cancer Res. 2003; 164:205-21.
Xu Y, Shibata A, McNeal JE, Stamey TA, Feldman D, Peehl DM. Vitamin D receptor start codon polymorphism (FokI) and prostate cancer progression. Cancer Epidemiol Biomarkers Prev. 2003 Jan; 12(1):23-7.
Shibata A, Garcia MI, Cheng I, Stamey TA, McNeal JE, Brooks JD, Henderson S, Yemoto CE, Peehl DM. Polymorphisms in the androgen receptor and type II 5 alpha-reductase genes and prostate cancer prognosis. Prostate. 2002 Sep 01; 52(4):269-78.
Kiviharju TM, Lecane PS, Sellers RG, Peehl DM. Antiproliferative and proapoptotic activities of triptolide (PG490), a natural product entering clinical trials, on primary cultures of human prostatic epithelial cells. Clin Cancer Res. 2002 Aug; 8(8):2666-74.
Vidanes GM, Paton V, Wallen E, Peehl DM, Navone N, Brooks JD. Silencing of pi-class glutathione S-transferase in MDA PCa 2a and MDA PCa 2b cells. Prostate. 2002 Jun 01; 51(4):225-30.
Guo X, Knudsen BS, Peehl DM, Ruiz A, Bok D, Rando RR, Rhim JS, Nanus DM, Gudas LJ. Retinol metabolism and lecithin:retinol acyltransferase levels are reduced in cultured human prostate cancer cells and tissue specimens. Cancer Res. 2002 Mar 15; 62(6):1654-61.
Ma JF, Takito J, Vijayakumar S, Peehl DM, Olsson CA, Al-Awqati Q. Prostatic expression of hensin, a protein implicated in epithelial terminal differentiation. Prostate. 2001 Sep 15; 49(1):9-18.
Miao H, Wei BR, Peehl DM, Li Q, Alexandrou T, Schelling JR, Rhim JS, Sedor JR, Burnett E, Wang B. Activation of EphA receptor tyrosine kinase inhibits the Ras/MAPK pathway. Nat Cell Biol. 2001 May; 3(5):527-30.
Peehl DM, Sellers RG. Cultured stromal cells: an in vitro model of prostatic mesenchymal biology. Prostate. 2000 Oct 01; 45(2):115-23.
Wallen E, Sellers RG, Peehl DM. Brefeldin A induces p53-independent apoptosis in primary cultures of human prostatic cancer cells. J Urol. 2000 Sep; 164(3 Pt 1):836-41.
Hukku B, Mally M, Cher ML, Peehl DM, Kung H, Rhim JS. Stepwise genetic changes associated with progression of nontumorigenic HPV-18 immortalized human prostate cancer-derived cell line to a malignant phenotype. Cancer Genet Cytogenet. 2000 Jul 15; 120(2):117-26.
Zhao XY, Peehl DM, Navone NM, Feldman D. 1alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms. Endocrinology. 2000 Jul; 141(7):2548-56.
Choi J, Shendrik I, Peacocke M, Peehl D, Buttyan R, Ikeguchi EF, Katz AE, Benson MC. Expression of senescence-associated beta-galactosidase in enlarged prostates from men with benign prostatic hyperplasia. Urology. 2000 Jul; 56(1):160-6.
Zhao XY, Malloy PJ, Krishnan AV, Swami S, Navone NM, Peehl DM, Feldman D. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat Med. 2000 Jun; 6(6):703-6.
Zhao XY, Boyle B, Krishnan AV, Navone NM, Peehl DM, Feldman D. Two mutations identified in the androgen receptor of the new human prostate cancer cell line MDA PCa 2a. J Urol. 1999 Dec; 162(6):2192-9.
Peehl DM, Sellers RG, Arnstein P, Kung HF, Rhim JS. Altered growth regulation and loss of response to retinoic acid accompany tumorigenic transformation of prostatic cells. Anticancer Res. 1999 Sep-Oct; 19(5B):3857-64.
Zhao XY, Ly LH, Peehl DM, Feldman D. Induction of androgen receptor by 1alpha,25-dihydroxyvitamin D3 and 9-cis retinoic acid in LNCaP human prostate cancer cells. Endocrinology. 1999 Mar; 140(3):1205-12.
Peehl DM. Vitamin D and prostate cancer risk. Eur Urol. 1999; 35(5-6):392-4.
Peehl DM, Sellers RG, Wong ST. Defined medium for normal adult human prostatic stromal cells. In Vitro Cell Dev Biol Anim. 1998 Jul-Aug; 34(7):555-60.
Stearns ME, Ware JL, Agus DB, Chang CJ, Fidler IJ, Fife RS, Goode R, Holmes E, Kinch MS, Peehl DM, Pretlow TG, Thalmann GN. Workgroup 2: human xenograft models of prostate cancer. Prostate. 1998 Jun 15; 36(1):56-8.
Peehl DM, Sellers RG. Basic FGF, EGF, and PDGF modify TGFbeta-induction of smooth muscle cell phenotype in human prostatic stromal cells. Prostate. 1998 May; 35(2):125-34.
Weijerman PC, Zhang Y, Shen J, Dubbink HJ, Romijn JC, Peehl DM, Schröder FH. Expression of prostatic factors measured by reverse transcription polymerase chain reaction in human papillomavirus type 18 deoxyribonucleic acid immortalized prostate cell lines. Urology. 1998 Apr; 51(4):657-62.
Zhao XY, Ly LH, Peehl DM, Feldman D. 1alpha,25-dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent. Endocrinology. 1997 Aug; 138(8):3290-8.
Peehl DM, Wong ST, Sellers RG, Jin S, Rhim JS. Loss of response to epidermal growth factor and retinoic acid accompanies the transformation of human prostatic epithelial cells to tumorigenicity with v-Ki-ras. Carcinogenesis. 1997 Aug; 18(8):1643-50.
Terris MK, Peehl DM. Human papillomavirus detection by polymerase chain reaction in benign and malignant prostate tissue is dependent on the primer set utilized. Urology. 1997 Jul; 50(1):150-6.
Nunn SE, Peehl DM, Cohen P. Acid-activated insulin-like growth factor binding protein protease activity of cathepsin D in normal and malignant prostatic epithelial cells and seminal plasma. J Cell Physiol. 1997 May; 171(2):196-204.
Peehl DM, Sellers RG. Induction of smooth muscle cell phenotype in cultured human prostatic stromal cells. Exp Cell Res. 1997 May 01; 232(2):208-15.
Peehl DM, Edgar MG, Cramer SD, Deftos LJ. Parathyroid hormone-related protein is not an autocrine growth factor for normal prostatic epithelial cells. Prostate. 1997 Apr 01; 31(1):47-52.
Cramer SD, Chen Z, Peehl DM. Prostate specific antigen cleaves parathyroid hormone-related protein in the PTH-like domain: inactivation of PTHrP-stimulated cAMP accumulation in mouse osteoblasts. J Urol. 1996 Aug; 156(2 Pt 1):526-31.
Miniati DN, Chang Y, Shu WP, Peehl DM, Liu BC. Role of prostatic basal cells in the regulation and suppression of human prostate cancer cells. Cancer Lett. 1996 Jul 12; 104(2):137-44.
Peehl DM, Sellers RG, McNeal JE. Keratin 19 in the adult human prostate: tissue and cell culture studies. Cell Tissue Res. 1996 Jul; 285(1):171-6.
Cramer SD, Peehl DM, Edgar MG, Wong ST, Deftos LJ, Feldman D. Parathyroid hormone--related protein (PTHrP) is an epidermal growth factor-regulated secretory product of human prostatic epithelial cells. Prostate. 1996 Jul; 29(1):20-9.
Bosland MC, Chung LW, Greenberg NM, Ho SM, Isaacs JT, Lane K, Peehl DM, Thompson TC, van Steenbrugge GJ, van Weerden WM. Recent advances in the development of animal and cell culture models for prostate cancer research A minireview. Urol Oncol. 1996 Jul-Aug; 2(4):99.
Turek PJ, Malkowicz SB, Tomaszewski JE, Wein AJ, Peehl D. The role of the Sertoli cell in active immunosuppression in the human testis. Br J Urol. 1996 Jun; 77(6):891-5.
Peehl DM, Wong ST, Rubin JS. KGF and EGF differentially regulate the phenotype of prostatic epithelial cells. Growth Regul. 1996 Mar; 6(1):22-31.
Peehl DM. Cellular biology of prostatic growth factors. Prostate Suppl. 1996; 6:74-8.
Peehl DM, Cohen P, Rosenfeld RG. The role of insulin-like growth factors in prostate biology. J Androl. 1996 Jan-Feb; 17(1):2-4.
Peehl DM, Wong ST, Cramer SD, Gross C, Feldman D. Suramin, hydrocortisone, and retinoic acid modify inhibitory effects of 1,25-dihydroxyvitamin D(3) on prostatic epithelial cells. Urol Oncol. 1995 Sep-Oct; 1(5):188-94.
Skowronski RJ, Peehl DM, Feldman D. Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3. Endocrinology. 1995 Jan; 136(1):20-6.
Peehl DM, Rubin JS. Keratinocyte growth factor: an androgen-regulated mediator of stromal-epithelial interactions in the prostate. World J Urol. 1995; 13(5):312-7.
Peehl DM, Cohen P, Rosenfeld RG. The insulin-like growth factor system in the prostate. World J Urol. 1995; 13(5):306-11.
Weijerman PC, König JJ, Wong ST, Niesters HG, Peehl DM. Lipofection-mediated immortalization of human prostatic epithelial cells of normal and malignant origin using human papillomavirus type 18 DNA. Cancer Res. 1994 Nov 01; 54(21):5579-83.
Peehl DM, Leung GK, Wong ST. Keratin expression: a measure of phenotypic modulation of human prostatic epithelial cells by growth inhibitory factors. Cell Tissue Res. 1994 Jul; 277(1):11-8.
Peehl DM, Skowronski RJ, Leung GK, Wong ST, Stamey TA, Feldman D. Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. Cancer Res. 1994 Feb 01; 54(3):805-10.
Weijerman PC, Romijn HC, Peehl DM. Human papilloma virus type 18 DNA immortalized cell lines from the human prostate epithelium. Prog Clin Biol Res. 1994; 386:67-9.
Pastan I, Lovelace E, Rutherford AV, Kunwar S, Willingham MC, Peehl DM. PR1--a monoclonal antibody that reacts with an antigen on the surface of normal and malignant prostate cells. J Natl Cancer Inst. 1993 Jul 21; 85(14):1149-54.
Skowronski RJ, Peehl DM, Feldman D. Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology. 1993 May; 132(5):1952-60.
Peehl DM. Oncogenes in prostate cancer. An update. Cancer. 1993 Feb 01; 71(3 Suppl):1159-64.
Peehl DM, Wong ST, Stamey TA. Vitamin A regulates proliferation and differentiation of human prostatic epithelial cells. Prostate. 1993; 23(1):69-78.
Yacoe ME, Sommer G, Peehl D. In vitro proton spectroscopy of normal and abnormal prostate. Magn Reson Med. 1991 Jun; 19(2):429-38.
Peehl DM, Wong ST, Stamey TA. Cytostatic effects of suramin on prostate cancer cells cultured from primary tumors. J Urol. 1991 Mar; 145(3):624-30.
Peehl DM, Wong ST, Terris MK, Stamey TA. Culture of prostatic epithelial cells from ultrasound-guided needle biopsies. Prostate. 1991; 19(2):141-7.
Peehl DM. Searching for suppressor genes in prostate cancer. Cancer Surv. 1991; 11:25-34.
Yaswen P, Smoll A, Peehl DM, Trask DK, Sager R, Stampfer MR. Down-regulation of a calmodulin-related gene during transformation of human mammary epithelial cells. Proc Natl Acad Sci U S A. 1990 Oct; 87(19):7360-4.
Peehl DM, Wong ST, McNeal JE, Stamey TA. Analysis of somatic cell hybrids derived from normal human prostatic epithelial cells fused with HeLa cells. Prostate. 1990; 17(2):123-36.
Kabalin JN, Peehl DM, Stamey TA. Clonal growth of human prostatic epithelial cells is stimulated by fibroblasts. Prostate. 1989; 14(3):251-63.
Peehl DM, Wong ST, Bazinet M, Stamey TA. In vitro studies of human prostatic epithelial cells: attempts to identify distinguishing features of malignant cells. Growth Factors. 1989; 1(3):237-50.
Peehl DM, Wong ST, Stamey TA. Clonal growth characteristics of adult human prostatic epithelial cells. In Vitro Cell Dev Biol. 1988 Jun; 24(6):530-6.
Peehl DM, Wehner N, Stamey TA. Activated Ki-ras oncogene in human prostatic adenocarcinoma. Prostate. 1987; 10(4):281-9.
Peehl DM, Stamey TA. Serum-free growth of adult human prostatic epithelial cells. In Vitro Cell Dev Biol. 1986 Feb; 22(2):82-90.
Peehl DM, Stamey TA. Growth responses of normal, benign hyperplastic, and malignant human prostatic epithelial cells in vitro to cholera toxin, pituitary extract, and hydrocortisone. Prostate. 1986; 8(1):51-61.
Brawer MK, Peehl DM, Stamey TA, Bostwick DG. Keratin immunoreactivity in the benign and neoplastic human prostate. Cancer Res. 1985 Aug; 45(8):3663-7.
